Participating Companies

4SC AG
[VSC:DB]
€23 MM MCap
An epigenetic focused company developing small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s lead compound, Resminostat, is focused on Cutaneous T Cell Lymphoma but has unpartnered assets for Hodkins Lymphona, Colorectal Cancer, and HCC. [more information]

Achilles Therapeutics
[ACHL]
$51 MM MCap
cNeT (clonal neoantigen) process builds on TILs, combined with ability to identify pt-specific clonal neoantigens and generate personalized T-cell therapies. Sep19 GBP100 million Series B w/ RA, Syncona, Forbion, Invus, Perceptive + Redmile. [more information]

Anavex Life Sciences Corp.
[AVXL]
$858 MM MCap
The analysis of RNA and whole exome DNA genome sequencing data has characterized several genomic alterations in well-characterized targets that can be used as biomarkers to identify optimal patients in forthcoming clinical trials (Rett, Alzheimer’s, and Parkinson’s). [more information]

Apeiron Investment Group LLC
Apeiron focuses on Financial Services (especially fintech and crypto assets), Technology, Life Sciences, Media & Entertainment and Real Estate & Prop-Tech. They invest in all phases and stages of a company’s life cycle, but focus on non-listed Seed/Start-up investments and larger size Restructuring & Special Situations deals (often listed). [more information]

Bain Capital Life Sciences
Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. [more information]

BioNTech AG
[BNTX]
$34,716 MM MCap
Through its diversified technology platforms and in-house diagnostics and manufacturing units, BioNTech is strategically positioned to implement its lab-bench-to-market strategy. [more information]

BlueStar Investment Managers SA (Onelife Advisors)
BlueStar is an asset management company headquartered in Lugano, Switzerland, specialising in managing investment funds and advising institutional clients on asset allocation, thematic investments and investment solutions. [more information]

Calliditas Therapeutics
[CALT]
$534 MM MCap
Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. [more information]

CFGI
CFGI - a portfolio company of The Carlyle Group - is an established national leader in providing operational finance and technical accounting services. [more information]

Crescendo Biologics
Crescendo Biologics is a clinical stage company developing T cell enhancing therapeutics.
Crescendo’s lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific. CB307’s unique format delivers tumour-specific killing, while avoiding systemic toxicity, and can be applied to a broad range of PSMA-positive cancer indications. It is designed to cause the proliferation of tumour-specific T cells, creating a safe, broad, longer-lasting anti-tumour response and will be in the clinic in early 2021. [more information]

CureVac
[CVAC]
$2,044 MM MCap
Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. [more information]

Ernst & Young
Ernst & Young Limited is a global leader in assurance, tax, transaction and advisory services. [more information]

Ethris
Ethris is pioneering the development of next-generation mRNA therapeutics and vaccines for respiratory diseases and infections with high unmet needs. [more information]

Glycostem Therapeutics
Glycostem Therapeutics is a Dutch biotech company. Glycostem Therapeutics is the trade name of the legal entity IPD Therapeutics BV, which has been established in December 2007.
Glycostem Therapeutics has developed the world's first GMP compliant NK-cell platform that is ready for industrial scale-up. [more information]

Goodwin Procter LLP
More than 1,000 corporate and litigation attorneys leverage their specific experience and assemble full-service teams to advise clients in these and adjacent industries. [more information]

H.C. Wainwright & Co., LLC
Wainwright & Company, Inc. is a full-service investment bank that offers equity research services to institutional and retail investors. Wainwright & Company, Inc was established in 1868 and is headquartered in New York City. Rodman & Renshaw is a sell side research wing of H.C. [more information]
Heights Capital Management, Inc.
Heights Capital Management, Inc. is a San Francisco based private equity firm specializing in private investments in public equity in emerging growth companies. [more information]

Immatics NV
[IMTX]
$633 MM MCap
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. [more information]

InflaRx N.V.
[IFRX]
$98 MM MCap
Complement system focused company, developing anti C5a mAbs with applications in complex cardiac surgery, hidradenits, ANCA assoc. Reported positive Ph2a results with IFX-1 in January 2015. Follow-on molecule, IFX-2, in pre-clinical development for additional sub-acute, chronic inflammatory indications. [more information]

invIOs
[more information]

iOnctura
iOnctura is a clinical-stage company applying insights in cancer biology to develop highly selective drugs that can simultaneously inhibit multiple tumor survival mechanisms. iOnctura’s drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology. [more information]

KBio
Creating the new generation of biologics using its plant-based platform that has demonstrated an ability to create potentially better drug candidates at a fraction of the time and cost of conventional platforms. Focused on discovering monoclonal antibodies targeting validated pathways for rare and infectious diseases and, due to the speed and accuracy of its antibody production system, is positioned well to develop fast follower therapies against validated drug targets. [more information]

Medigene AG
[MDG1:DB]
€51 MM MCap
bluebird bio collab; BLUE initiating trial w/MDG MAGEA-4 candidate in 2020. TCRs targeting HA-1 & MAGE-A1 in devt. . DC vax in ongoing Ph 1/2; final readout in 2019. [more information]

Monte Rosa Therapeutics
[GLUE]
$350 MM MCap
Multi-asset next-gen AI-driven molecular glue-based TPD platform. Lead program in Ph 1 focused on GSPT1, a key regulator and vulnerability of MYC-driven solid tumors, including lung cancer. [more information]

MorphoSys AG
[MOR]
$691 MM MCap
Its partnered discovery segment applies the research, development, and optimization of antibody-drug candidates in partnerships with pharmaceutical and biotechnology companies. In its proprietary development segment, the company develops antibodies that concentrate on inflammatory and autoimmune diseases, as well as cancer and infectious diseases. [more information]

Nasdaq, Inc.
[NDAQ]
$29,469 MM MCap
Nasdaq is primarily known for its equity exchange, but in addition to its market services business (about 35% of sales), the company sells and distributes exchange data through its information services segment (30%). Information services offers Nasdaq-branded indexes to asset managers and investors. [more information]

NautaDutilh
Founded in 1724, NautaDutilh has grown to become one of the largest in the Benelux with over 400 lawyers, civil law notaries and tax advisers at offices in Amsterdam, Brussels, London, Luxembourg, New York and Rotterdam. It allows NautaDutilh lawyers to deal with change, learn from new situations and think on their feet when solving problems on behalf of our clients. [more information]

Nykode Therapeutics
[NYKD]
Clinical stage immunotherapy company focused on cancer and infectious disease. Modular vaccine technology targets antigens to Antigen Presenting Cells to achieve rapid, strong and long-lasting immune responses. Key programs include Ph2 proprietary HPV 16+ cervical cancer therapeutic vaccine, Ph1/2 individualized cancer neoantigen vaccine (Genentech), Ph1/2 next-generation COVID-19 T-cell vaccines. Significant collaborations with Regeneron, Genentech, Adaptive Biotechnologies. [more information]

Oryzon Genomics
[ORY]
Targeting lysine specific demethylase 1 (LSD1, aka KDM1A). Lead CNS compound in 3 Phase 2a trials in MS, AD and basket trial. Onc compound in 2 combo Phase 2a trials in AML and SCLC. Data exp mid-2019 [more information]

Phenex Pharmaceuticals AG
Phenex is a privately held drug discovery and development company headquartered in Ludwigshafen with a major research site in Heidelberg. It is the company ́s goal to partner and outlicense drug programs in areas with major market potential to global players from the biopharmaceutical industry while pursuing own drug development in niche areas with particular high medical needs. [more information]

Priothera
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. [more information]

PROSION
A pharmaceutical drug discovery company with proline derived modules (ProMs) as the world’s first PRM structure mimicking building blocks. The company develops a new class of drugs and is able to address yet undruggable considered targets that are related to various indications. For its first of many use-cases, PROSION has already shown a remarkable in vivo effect of its ProM-based anti-metastatic inhibitor – both in pancreatic and breast cancer xenograft rodent models. [more information]

Silicon Valley Bank
Silicon Valley Bank is a provider of commercial and private banking services. The bank offers online and banking services, payments, deposits and fraud prevention services. Silicon Valley Bank was founded in 1983 and is headquartered in Santa Clara, California. [more information]

Solebury Strategic Communications
With almost two decades of experience in the biotechnology, pharmaceutical, medical technology and life science technology sectors, the Trout Group offers its clients the knowledge base needed to clarify investment themes and leverage key relationships for increased exposure to the proper audience. [more information]

SOTIO a.s.
The company operates as a biotechnology firm which develops new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies, enabling state-of-the-art immunotherapy treatment for its patients in Prague, Czech Republic. [more information]

SphingoTec GmbH
SphingoTec’s first-in-class tests are made available on its proprietary whole-blood point-of-care Nexus IB10 platform for convenient and rapid testing in near-patient and laboratory settings alongside a broad portfolio of standard-of-care test for acute care. [more information]

sterna biologicals
By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company’s proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase 2 development. [more information]

Targovax
[TRVX]
Preliminary Ph1b data of OV ONCOS-102+chemo in mesothelioma results: combo mPFS=8.4 mos. vs. control mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Upcoming milestones: updated clinical & immune data in Ph2 mesothelioma (1H20); preclinical data on next-gen OV w/ double transgenes (1H20); and clinical data from Ph1 melanoma study, part 2 with extended dosing (2H20). [more information]

Tonix Pharmaceuticals
[TNXP]
$67 MM MCap
The company is engaged in discovering, licensing, acquiring and developing drugs and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes biologics to prevent infectious diseases and small molecules and biologics to treat pain, psychiatric and addiction conditions. [more information]

Vivoryon
[VVY:AS]
€333 MM MCap
Develops small molecule medicines that modulate the activity and stability of pathologically altered proteins. Lead candidate varoglutamstat, currently in VIVIAD EU Ph2b and VIVA-MIND US Ph2a/2b studies in Alzheimer’s disease (AD), targets all three major hallmarks of AD (Abeta pathology, tau pathology, neuroinflammation) and synaptic impairment. [more information]

Wellington Partners
Founded in 1998, Wellington Partners is a venture capital firm based in Munich, Germany. The firm seeks to invest in the early- and growth-stage technology and life science sectors. [more information]